Table 1.
Demographic, baseline, and disease characteristics of patients with leiomyosarcoma
| Characteristic | Eribulin (n = 157) | Dacarbazine (n = 152) | Total (N = 309) |
|---|---|---|---|
| Median age (minimum, maximum), years | 57 (28, 76) | 56 (24, 77) | 57 (24, 77) |
| Age group, n (%), years | |||
| <65 | 123 (78) | 124 (82) | 247 (80) |
| ≥65 | 34 (22) | 28 (18) | 62 (20) |
| Sex, n (%) | |||
| Male | 29 (18) | 31 (20) | 60 (19) |
| Female | 128 (82) | 121 (80) | 249 (81) |
| Race, n (%) | |||
| White | 110 (70) | 117 (77) | 227 (74) |
| African American | 6 (4) | 4 (3) | 10 (3) |
| Asiana | 14 (9) | 12 (8) | 26 (8) |
| Otherb | 27 (17) | 19 (12) | 46 (15) |
| ECOG PS, n (%) | |||
| 0 | 76 (48) | 66 (43) | 142 (46) |
| 1 | 80 (51) | 79 (52) | 159 (52) |
| 2 | 1 (1) | 7 (5) | 8 (3) |
| Histology subcategory, n (%) | |||
| Uterine | 68 (43) | 63 (41) | 131 (42) |
| Nonuterine | 88 (56) | 89 (59) | 177 (57) |
| Tumour grade, n (%) | |||
| High | 112 (71) | 113 (74) | 225 (73) |
| Intermediate | 45 (29) | 37 (24) | 82 (27) |
| Not done | 0 | 2 (1) | 2 (1) |
| Geographic region, n (%) | |||
| USA and Canada | 62 (40) | 61 (40) | 123 (40) |
| Western Europe, Australasia, Israel | 70 (45) | 68 (45) | 138 (45) |
| Eastern Europe, Latin America, Asia | 25 (16) | 23 (15) | 48 (16) |
| Median age at diagnosis (minimum, maximum), years | 53.0 (24, 75) | 52.5 (23, 75) | 53.0 (23, 75) |
| Previous anticancer therapy,c n (%) | |||
| 0 | 0 | 0 | 0 |
| 1 | 2 (1) | 1 (1) | 3 (1) |
| 2 | 76 (48) | 70 (46) | 146 (47) |
| 3 | 44 (28) | 44 (29) | 88 (28) |
| 4 | 17 (11) | 25 (16) | 42 (14) |
| >4 | 18 (12) | 12 (8) | 30 (10) |
ECOG PS Eastern Cooperative Oncology Group performance status
aIncludes Japanese, Chinese, and other Asian
bIncludes American Indian or Alaskan Native, Native Hawaiian or Other Pacific Islander, other, and not applicable
cExcludes radiotherapy and surgery